Sato Madoka, Hanafusa Norio, Kawaguchi Hiroshi, Tsuchiya Ken, Nitta Kosaku
Department of Nephrology, Jyoban Hospital, Fukushima, Japan.
Departments of Blood Purification Tokyo Women's Medical University, Tokyo, Japan.
Kidney Blood Press Res. 2018;43(3):1023-1033. doi: 10.1159/000490824. Epub 2018 Jun 21.
BACKGROUND/AIMS: Potential relationships between serum sclerostin levels and the levels of bone metabolic markers in maintenance hemodialysis (MHD) patients have yet to be evaluated. This study sought to determine whether serum sclerostin levels are associated with mortality in MHD patients.
We measured serum sclerostin levels in a Japanese MHD cohort, classified the patients into tertiles according to these levels, and followed their course for a 42-month period.
The cohort consisted of 389 MHD patients and there were 75 deaths. Kaplan-Meier analyses showed that the tertile of serum sclerostin was not associated with mortality risk. Cox analyses showed that there were no significant associations between serum sclerostin level and mortality.
Serum sclerostin level was not an independent predictor of mortality in MHD patients after adjustment for several confounders. However, whether clinical interventions to modulate serum sclerostin levels in MHD patients would improve their survival remains to be determined.
背景/目的：维持性血液透析（MHD）患者血清硬化蛋白水平与骨代谢标志物水平之间的潜在关系尚未得到评估。本研究旨在确定血清硬化蛋白水平是否与MHD患者的死亡率相关。
我们测量了一组日本MHD患者的血清硬化蛋白水平，根据这些水平将患者分为三个三分位数，并对他们进行了42个月的随访。
该队列由389例MHD患者组成，其中75例死亡。Kaplan-Meier分析表明，血清硬化蛋白三分位数与死亡风险无关。Cox分析表明，血清硬化蛋白水平与死亡率之间无显著关联。
在调整了几个混杂因素后，血清硬化蛋白水平不是MHD患者死亡率的独立预测因素。然而，调节MHD患者血清硬化蛋白水平的临床干预措施是否能改善其生存率仍有待确定。
